Regorafenib in Relapsed Glioblastoma. An Observational, Multicentric and Prospective Study. IOV-GB-1-2020 REGOMA-OSS
Latest Information Update: 13 Feb 2024
At a glance
- Drugs Regorafenib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms IOV-GB-1-2020 REGOMA-OSS; REGOMA-OSS
- 30 Oct 2023 Planned End Date changed from 1 Oct 2022 to 1 Dec 2023.
- 30 Oct 2023 Planned primary completion date changed from 1 Oct 2022 to 1 Dec 2023.
- 30 Oct 2023 Status changed from recruiting to active, no longer recruiting.